Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditionsView Altmetrics View AltmetricsTools Mody, K. T., Mahony, D., Cavallaro, A. S., Stahr, F., Qiao, S. Z., Mahony, T. J. and Mitter, N. (2014) Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditions. International Journal of Pharmaceutics . ISSN 0378-5173 Full text not currently attached. Access may be available via the Publisher's website or OpenAccess link. Article Link: http://dx.doi.org/10.1016/j.ijpharm.2014.01.037 AbstractAmino functionalised mesoporous silica nanoparticles (AM-41) have been identified as a promising vaccine delivery material. The capacity of AM-41 to stabilise vaccine components at ambient temperature (23–27 °C) was determined by adsorbing the model antigen ovalbumin (OVA) to AM-41 particles (OVA-41). The OVA-41 was successfully freeze-dried using the excipients 5% trehalose and 1% PEG8000. Both the immunological activity of OVA and the nanoparticle structure were maintained following two months storage at ambient temperature. The results of immunisation studies in mice with reconstituted OVA-41 demonstrated the induction of humoral and cell-meditated immune responses. The capacity of AM-41 particles to facilitate ambient storage of vaccine components without loss of immunological potency will underpin the further development of this promising vaccine delivery platform.
Repository Staff Only: item control page |